Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

European Journal of Heart Failure

Volumn 19, Issue 12, 2017, Pages 1586-1596

  Rickenbacher, Peter ^a,b   Kaufmann, Beat A ^a   Maeder, Micha T ^c   Bernheim, Alain ^d   Goetschalckx, Kaatje ^e   Pfister, Otmar ^a   Pfisterer, Matthias ^a   Brunner La Rocca, Hans Peter ^a,f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Bruderholz   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Heart failure; Heart failure with mid range ejection fraction; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT;

ADULT; ANEMIA; AORTIC ANEURYSM; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMENTIA; DEPRESSION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GOUT; HEART FAILURE; HEART FAILURE WITH MID-RANGE EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY; MULTICENTER STUDY; OSTEOARTHRITIS; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; SURVIVAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; DISEASE MANAGEMENT; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; DISEASE MANAGEMENT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 85015257096     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.798     Document Type: Article

References (27)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola V, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.
3. Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 2014;35:1022–1032.
4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Östergren J, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.
5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, for the I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467.
6. Pitt B, Pfeffer MA, Assmann S, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Rafael Diaz R, Fleg JL, Gordeev J, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, for the TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.
7. Lam CSP, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014;16:1049–1055.
8. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M, for the TIME-CHF Investigators. Management of elderly patients with congestive heart failure—Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006;151:949–955.
9. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon S, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP, for the TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF Randomized Trial). JAMA 2009;301:383–392.
10. Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP, for the TIME-CHF Investigators. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2013;15:1148–1156.
11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt J. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1–39.
12. Kaufmann BA, Min SY, Goetschalckx K, Bernheim AM, Buser PT, Pfisterer ME, Brunner-La Rocca HP. How reliable are left ventricular ejection fraction cut offs assessed by echocardiography for clinical decision making in patients with heart failure? Int J Cardiovasc Imaging 2013;29:581–588.
13. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GA, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631–639.
14. Solomon SD, Anavekar N, Skali H, McMurray JJV, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA, for the Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738–3744.
15. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade G, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, for the OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol 2007;50:768–777.
16. He KL, Burkhoff D, Leng WX, Leng W, Liang Z, Fan L, Wang J, Maurer MS. Comparison of left ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40 to 55% versus <40%. Am J Cardiol 2009;103:845–851.
17. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction. Prevalence, outcome and therapies. Circulation 2012;126:65–75.
18. Toma M, Ezekowitz JA, Bakal JA, O'Connor CM, Hernandez AF, Sardar MR, Zolty R, Massie BM, Swedberg K, Armstrong PW, Starling RC. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. Eur J Heart Fail 2014;16:334–341.
19. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (≥55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol 2008;101:1151–1156.
20. Nadruz W, West E, Santos M, Skali H, Groarke JD, Forman DE, Shah AM. Heart failure and midrange ejection fraction. Implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail 2016;9:e002826.
21. Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, Woodward M, Patel A, McMurray J, MacMahon S. Risk prediction in patients with heart failure. A systematic review and analysis. JACC Heart Fail 2014;2:440–446.
22. Hwang S, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014;63:2817–2827.
23. Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy C. Coronary artery disease and 10 year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 2014;16:967–976.
24. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002; 90:1284–1289.
25. Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 2015;8:295–303.
26. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Jerome L. Fleg JL, Sopko G, Pitt B, Pfeffer MA for the TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455–462.
27. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750–1757.